Pressmeddelanden • Apr 19, 2018 08:01 CEST
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) mutations, (exon 19 deletions or exon 21 L858R mutations), as detected by an FDA-approved test.
Updated overall survival data for Lynparza in BRCA-mutated HER2-negative metastatic breast cancer presented at AACR
Pressmeddelanden • Apr 16, 2018 08:01 CEST
AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today presented data from the Phase III OlympiAD trial showing the final overall survival (OS) results for Lynparza (olaparib) in metastatic breast cancer at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, US, 14-18 April 2018.
1st-line Tagrisso demonstrates sustained benefit post progression in patients with EGFR-mutated non-small cell lung cancer
Pressmeddelanden • Apr 13, 2018 16:58 CEST
AstraZeneca today presented new post-progression outcomes data from an exploratory analysis of the global Phase III FLAURA trial, which assessed the efficacy and safety of Tagrisso (osimertinib) as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Pressmeddelanden • Apr 04, 2018 12:01 CEST
AstraZeneca and MedImmune, its global biologics research and development arm, will present updates from their early and late stage oncology pipelines at two major congresses this month. In total, 98 abstracts were accepted for the European Lung Cancer Conference (ELCC) in Geneva,11-14 April, and the American Association for Cancer Research (AACR) annual meeting in Chicago,14-18 April.
The European Medicines Agency accepts regulatory submission for Lynparza in BRCA-mutated, HER2-negative metastatic breast cancer
Pressmeddelanden • Apr 03, 2018 08:03 CEST
AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced that the European Medicines Agency has validated for review the Marketing Authorisation Application (MAA) for Lynparza (olaparib).
Pressmeddelanden • Apr 03, 2018 08:03 CEST
AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for moxetumomab pasudotox, an investigational anti-CD22 recombinant immunotoxin and a potential new medicine for the treatment of adult patients with hairy cell leukaemia (HCL).
Pressmeddelanden • Mar 22, 2018 17:58 CET
Pressmeddelanden • Mar 14, 2018 14:13 CET
Pressmeddelanden • Mar 12, 2018 08:04 CET
AstraZeneca and MedImmune, today announced an updated timeline for the final analysis of the Phase III MYSTIC trial of Imfinzi (durvalumab). Based on current predictions, the final analysis of overall survival (OS) is now expected in the second half of 2018 (previously anticipated in the first half).
New data from landmark CVD-REAL study of patients with type-2 diabetes confirms CV benefits associated with SGLT-2 inhibitors
Pressmeddelanden • Mar 11, 2018 21:51 CET
Real-world evidence study of more than 400,000 patients with type-2 diabetes, 74% of whom did not have a history of established cardiovascular disease, supports the association of CV benefits with use of Farxiga Latest analysis includes heart attack and stroke endpoints, longer follow-up period and six additional countries across Asia Pacific, the Middle East and North America
The European medicines agency accepts regulatory submission for Forxiga in adults with type-1 diabetes
Pressmeddelanden • Mar 05, 2018 14:46 CET
First European filing acceptance of a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor in type-1 diabetes
Pressmeddelanden • Mar 05, 2018 14:42 CET
10 abstracts including three late breakers presenting new Phase III data and landmark real-world evidence from Asia, Middle East and North America
Pressmeddelanden • Feb 28, 2018 08:03 CET
AstraZeneca today announced that its global biologics research and development arm, MedImmune, is spinning out six molecules fromits early-stage inflammation and autoimmunity programmes into an independent biotech company, Viela Bio.
Pressmeddelanden • Feb 23, 2018 13:37 CET
AstraZeneca and MSD’s new Lynparza tablet formulation recommended for maintenance therapy regardless of BRCA status
Pressmeddelanden • Feb 17, 2018 08:12 CET
Imfinzi is the only immunotherapy approved for patients with unresectable Stage III non-small cell lung cancer Imfinzi showed an 11.2 month improvement in median progression-free survival (16.8 months compared to 5.6 months on placebo)
Pressmeddelanden • Feb 15, 2018 08:05 CET
AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1).
Brilinta significantly reduces CV events and coronary death beyond one year in heart attack survivors with multi-vessel disease
Pressmeddelanden • Feb 07, 2018 08:04 CET
Study reveals prolonging treatment with Brilinta 60mg after one year, reduces risk of major adverse cardiac events (MACE) by 19% and coronary death by 36%1 Builds on analysis2 showing 5-year ischaemic risk post-heart attack and benefits of long-term cardiovascular (CV) protection with Brilinta 60mg
Pressmeddelanden • Feb 02, 2018 08:05 CET
Positiv utveckling avseende kommersiellt genomförande och kostnadsdisciplin; produktförsäljningen ökade under kvartalet. AstraZeneca står inför tillväxt i produktförsäljningen för helåret 2018
AstraZeneca reports top-line phase III KRONOS trial results for PT010 triple combination therapy in chronic obstructive pulmonary disease
Pressmeddelanden • Jan 26, 2018 08:06 CET
AstraZeneca today announced top-line results from the Phase III KRONOS trial that showed PT010 (budesonide/glycopyrronium/formoterol fumarate 320/14.4/9.6µg, using Aerosphere Delivery Technology, in a pressurised metered-dose inhaler or pMDI) demonstrated a statistically significant improvement compared with dual combination therapies in six out of seven lung function primary endpoints.